149 related articles for article (PubMed ID: 19654409)
1. Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice.
Pan J; Liu T; Kim JY; Zhu D; Patel C; Cui ZH; Zhang X; Newgren JO; Reames A; Canivel D; Jesmok G; Pierce GF; Sommer JM; Jiang H
Blood; 2009 Sep; 114(13):2802-11. PubMed ID: 19654409
[TBL] [Abstract][Full Text] [Related]
2. Passive transfer of polyethylene glycol to liposomal-recombinant human FVIII enhances its efficacy in a murine model for hemophilia A.
Ramani K; Purohit V; Miclea R; Gaitonde P; Straubinger RM; Balu-Iyer SV
J Pharm Sci; 2008 Sep; 97(9):3753-64. PubMed ID: 18300296
[TBL] [Abstract][Full Text] [Related]
3. Report on 4 cases with decreased recovery due to neutralizing antibodies specific for PEGylated recombinant factor VIII.
Hillarp A; Holme PA; Wåland EP; Le MS; Henriksson CE; Tjønnfjord GE; Måseide RJ
J Thromb Haemost; 2023 Oct; 21(10):2771-2775. PubMed ID: 37543216
[TBL] [Abstract][Full Text] [Related]
4. Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products.
Simpson ML; Desai V; Maro GS; Yan S
J Manag Care Spec Pharm; 2020 Apr; 26(4):504-512. PubMed ID: 32020842
[TBL] [Abstract][Full Text] [Related]
5. Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A.
Powell JS; Nugent DJ; Harrison JA; Soni A; Luk A; Stass H; Gorina E
J Thromb Haemost; 2008 Feb; 6(2):277-83. PubMed ID: 18039351
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A.
Spira J; Plyushch OP; Andreeva TA; Khametova RN
Thromb Haemost; 2008 Sep; 100(3):429-34. PubMed ID: 18766258
[TBL] [Abstract][Full Text] [Related]
7. BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation.
Turecek PL; Bossard MJ; Graninger M; Gritsch H; Höllriegl W; Kaliwoda M; Matthiessen P; Mitterer A; Muchitsch EM; Purtscher M; Rottensteiner H; Schiviz A; Schrenk G; Siekmann J; Varadi K; Riley T; Ehrlich HJ; Schwarz HP; Scheiflinger F
Hamostaseologie; 2012; 32 Suppl 1():S29-38. PubMed ID: 22961422
[TBL] [Abstract][Full Text] [Related]
8. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models.
Stennicke HR; Kjalke M; Karpf DM; Balling KW; Johansen PB; Elm T; Øvlisen K; Möller F; Holmberg HL; Gudme CN; Persson E; Hilden I; Pelzer H; Rahbek-Nielsen H; Jespersgaard C; Bogsnes A; Pedersen AA; Kristensen AK; Peschke B; Kappers W; Rode F; Thim L; Tranholm M; Ezban M; Olsen EH; Bjørn SE
Blood; 2013 Mar; 121(11):2108-16. PubMed ID: 23335368
[TBL] [Abstract][Full Text] [Related]
9. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment.
Mei B; Pan C; Jiang H; Tjandra H; Strauss J; Chen Y; Liu T; Zhang X; Severs J; Newgren J; Chen J; Gu JM; Subramanyam B; Fournel MA; Pierce GF; Murphy JE
Blood; 2010 Jul; 116(2):270-9. PubMed ID: 20194895
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII.
Hermans C; Mahlangu J; Booth J; Schütz H; Santagostino E; Young G; Lee HY; Steinitz-Trost KN; Blanchette V; Berntorp E
Haemophilia; 2018 May; 24(3):376-384. PubMed ID: 29732708
[TBL] [Abstract][Full Text] [Related]
11. Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes.
Spira J; Plyushch OP; Andreeva TA; Andreev Y
Blood; 2006 Dec; 108(12):3668-73. PubMed ID: 16888098
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Pharmacokinetic Properties of Extended Half-Life and Recombinant Factor VIII Concentrates by In Silico Simulations.
Bukkems LH; Preijers T; van Spengler MWF; Leebeek FWG; Cnossen MH; Mathôt RAA
Thromb Haemost; 2021 Jun; 121(6):731-740. PubMed ID: 33506481
[TBL] [Abstract][Full Text] [Related]
13. Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy.
Baru M; Carmel-Goren L; Barenholz Y; Dayan I; Ostropolets S; Slepoy I; Gvirtzer N; Fukson V; Spira J
Thromb Haemost; 2005 Jun; 93(6):1061-8. PubMed ID: 15968389
[TBL] [Abstract][Full Text] [Related]
14. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs.
Dumont JA; Liu T; Low SC; Zhang X; Kamphaus G; Sakorafas P; Fraley C; Drager D; Reidy T; McCue J; Franck HW; Merricks EP; Nichols TC; Bitonti AJ; Pierce GF; Jiang H
Blood; 2012 Mar; 119(13):3024-30. PubMed ID: 22246033
[TBL] [Abstract][Full Text] [Related]
15. PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia A mice.
Peng A; Kosloski MP; Nakamura G; Ding H; Balu-Iyer SV
AAPS J; 2012 Mar; 14(1):35-42. PubMed ID: 22173945
[TBL] [Abstract][Full Text] [Related]
16. Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model.
Rode F; Almholt K; Petersen M; Kreilgaard M; Kjalke M; Karpf DM; Groth AV; Johansen PB; Larsen LF; Loftager M; Haaning J
J Thromb Haemost; 2018 Jun; 16(6):1141-1152. PubMed ID: 29582559
[TBL] [Abstract][Full Text] [Related]
17. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice.
Seth Chhabra E; Liu T; Kulman J; Patarroyo-White S; Yang B; Lu Q; Drager D; Moore N; Liu J; Holthaus AM; Sommer JM; Ismail A; Rabinovich D; Liu Z; van der Flier A; Goodman A; Furcht C; Tie M; Carlage T; Mauldin R; Dobrowsky TM; Liu Z; Mercury O; Zhu L; Mei B; Schellenberger V; Jiang H; Pierce GF; Salas J; Peters R
Blood; 2020 Apr; 135(17):1484-1496. PubMed ID: 32078672
[TBL] [Abstract][Full Text] [Related]
18. Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A.
Ramani K; Miclea RD; Purohit VS; Mager DE; Straubinger RM; Balu-Iyer SV
J Pharm Sci; 2008 Apr; 97(4):1386-98. PubMed ID: 17705286
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A.
Coyle TE; Reding MT; Lin JC; Michaels LA; Shah A; Powell J
J Thromb Haemost; 2014 Apr; 12(4):488-96. PubMed ID: 24843882
[TBL] [Abstract][Full Text] [Related]
20. Biological activity of a new recombinant human coagulation factor VIII and its efficacy in a small animal model.
Wu J; Zhang H; Lian T; Ding Y; Song C; Li D; Wu L; Lei T; Liang H
Biochem Biophys Res Commun; 2023 Jan; 640():80-87. PubMed ID: 36502635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
